Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

Markets at a glance
The markets staged a recovery after a steep correction during the first half of last week. The trading was characterised by bouts of sharp intra-day volatility, especially in the last three trading sessions. The BSE Sensex managed to cross the 16,000 level during the last sessions of the week. During the week, the Sensex rose 262 points or 1.65 per cent to 16,158, while Nifty rose 84 points or 1.79 per cent to 4,796. However, mid-caps outperformed the broader indices during the week, whereas small-caps underperformed. FIIs were net sellers initially, but started buying during the second half of the week.

payday loans online
Chandrayaan-II will be a technical challenge: Mission director
India’s second mission to Moon ‘Chandrayaan-II’, expected to be launched in 2013, has many challenges for scientists and engineers, mission director M Annadurai said today.

News of the day

Volumes fall on Day 1 of extended trading
Extended trading hours starting today did nothing to boost the volumes on the bourses that opened nearly an hour earlier at 0900 hrs, as part of conscious efforts to align trade timing with the Asian markets.
Public Company

Opto Circuits gets CE nod for drug sale

Life Sciences technology firm, Opto Circuits, a wholly-owned subsidiary Eurocor has received Communite European (CE) approval to market and sale its Drug Eluting Stent- Taxcor Plus in the world markets. - Opto to invest Rs 200 cr for units in Vizag, Malaysia - Opto Circuits net up 18% in Q2 - Opto Circuits" US arm signs multi-year supply contract with US firm - Criticare Systems enters into agreement with European firm - Opto Circuits" US arm in supply pact with European firm - Opto Circuits raises Rs 400 cr from QIP issue "Taxcor Plus is backed by years of research and has shown excellent clinical results," Opto Circuits Chairman & Managing Director Vinod Ramnani said. The product provides unique therapeutic benefits to patients requiring Drug Eluting Stents for Coronary Angioplasty. However, the company cannot sell this drug in the US and Japan markets under the terms of the agreement, it said.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009